[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]

David Beauvais; Emmanuel Bachy; André Baruchel; Jacques-Olivier Bay; Denis Caillot; Guillaume Cartron; Gandhi Damaj; Sabine Furst; Steven Le Gouill; Franck Morschhauser; Florence Rabian; Marie-Thérèse Rubio; Catherine Thieblemont; Ibrahim Yakoub-Agha

doi:10.1016/j.bulcan.2020.10.017

[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]

Bull Cancer. 2021 Jul-Aug;108(7-8):725-729. doi: 10.1016/j.bulcan.2020.10.017. Epub 2021 Jan 7.

[Article in French]

Authors

Affiliations

¹ CHU de Lille, université de Lille, hôpital Huriez, service des maladies du sang, Lille, France. Electronic address: david.beauvais@chru-lille.fr.
² Hôpital Lyon Sud, Université Lyon 1 Claude Bernard, service d'hématologie clinique, Pierre-Bénite, France.
³ Université de Paris, hôpital universitaire Robert-Debré (AP-HP), institut de recherche Saint-Louis (EA 35-18), service d'hématologie-immunologie pédiatrique, Paris, France.
⁴ CHU de Clermont-Ferrand, department of hematology, Clermont-Ferrand, France.
⁵ CHU Dijon, hematologie clinique, Dijon, France.
⁶ CHU Montpellier, institut de génétique moléculaire de Montpellier, département d'hématologie, UMR-CNRS 5535, Montpellier, France.
⁷ Université Caen-Normandie, institut d'hématologie, CHU de Caen, Caen, France.
⁸ Institut Paoli Calmettes, department of hematology, Marseille, France.
⁹ CHU de Nantes, université de Nantes, service d'hématologie clinique, Inserm CRCINA, Nantes, France.
¹⁰ CHU de Lille, université de Lille, hôpital Huriez, service des maladies du sang, Lille, France.
¹¹ Université de Paris, hôpital Saint-Louis (AP-HP), institut de recherche Saint-Louis (EA 35-18), unité d'hématologie adolescents et jeunes adultes, Paris, France.
¹² CHRU Nancy, Biopole de l'université de Lorraine, hôpital Brabois, service d'hématologie, CNRS UMR 7365, Nancy, France.
¹³ AP-HP, Paris - université de Paris - Paris Diderot, hôpital Saint-Louis, service hémato-oncologie, Paris, France.
¹⁴ CHU de Lille, université Lille, Inserm U1286, Infinite, Lille, France.

PMID: 33423776
DOI: 10.1016/j.bulcan.2020.10.017

Abstract

The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (Kymriah^TM) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (Yescarta^TM) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologous T-cells directed against CD19. This collaborative work, part of a series of expert opinion-based work, aims to give practical advice to help centers in selection of patients for commercially available CAR T-cell treatment.

Keywords: B-cell acute lymphoblastic leukemia; CAR T-cells; CD19; Cellules CAR-T; Diffuse large B-cell lymphoma; Leucémie aiguë lymphoblastique B; Lymphome diffus à grandes cellules B.

Publication types

Review

MeSH terms

Antigens, CD19 / therapeutic use*
Biological Products
Child
Europe
Humans
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse / therapy
Mediastinal Neoplasms / therapy
Patient Selection*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
Receptors, Antigen, T-Cell / therapeutic use*
Receptors, Chimeric Antigen*
Substance-Related Disorders
Young Adult

Substances

Antigens, CD19
Biological Products
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
tisagenlecleucel
axicabtagene ciloleucel